IN2014CN01970A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN01970A IN2014CN01970A IN1970CHN2014A IN2014CN01970A IN 2014CN01970 A IN2014CN01970 A IN 2014CN01970A IN 1970CHN2014 A IN1970CHN2014 A IN 1970CHN2014A IN 2014CN01970 A IN2014CN01970 A IN 2014CN01970A
- Authority
- IN
- India
- Prior art keywords
- biomarkers
- event
- years
- risk
- methods
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 239000012472 biological sample Substances 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541828P | 2011-09-30 | 2011-09-30 | |
| PCT/US2012/058060 WO2013049674A1 (en) | 2011-09-30 | 2012-09-28 | Cardiovascular risk event prediction and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN01970A true IN2014CN01970A (enrdf_load_html_response) | 2015-05-29 |
Family
ID=47993164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1970CHN2014 IN2014CN01970A (enrdf_load_html_response) | 2011-09-30 | 2012-09-28 |
Country Status (16)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10359425B2 (en) | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| WO2011154689A1 (en) * | 2010-06-07 | 2011-12-15 | King's College London | Methods and means for predicting or diagnosing diabetes or cardiovascular disorders based on micro rna detection |
| SG10201508656VA (en) | 2010-07-09 | 2015-11-27 | Somalogic Inc | Lung cancer biomarkers and uses thereof |
| SG2014007454A (en) | 2010-08-13 | 2014-07-30 | Somalogic Inc | Pancreatic cancer biomarkers and uses thereof |
| EP2683729B1 (en) | 2011-03-10 | 2017-05-03 | Somalogic, Inc. | Aptamers for clostridium difficile diagnostics |
| KR102111624B1 (ko) * | 2011-09-30 | 2020-05-18 | 소마로직, 인크. | 심혈관 위험 사건 예측 및 그것의 용도 |
| US20130252835A1 (en) | 2012-01-27 | 2013-09-26 | Lian Chye Winston Koh | Methods for profiling and quantitating cell-free rna |
| JP6198047B2 (ja) * | 2013-08-02 | 2017-09-20 | 国立大学法人岐阜大学 | 冠動脈疾患の検査キット |
| CN114703193A (zh) | 2013-09-24 | 2022-07-05 | 私募蛋白质体运营有限公司 | 多适配子靶标检测 |
| WO2015140317A1 (en) * | 2014-03-21 | 2015-09-24 | Sanofi | New markers for the assessment of the risk for development of a cardiovascular disorder |
| EP3633382A1 (en) * | 2014-06-05 | 2020-04-08 | Sanofi-Aventis Deutschland GmbH | New markers for the assessment of an increased risk for mortality |
| ES2792227T3 (es) * | 2014-09-26 | 2020-11-10 | Somalogic Inc | Predicción de evento de riesgo cardiovascular y usos de la misma |
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| US20190017117A1 (en) * | 2015-07-10 | 2019-01-17 | West Virginia University | Markers of stroke and stroke severity |
| RU2602451C1 (ru) * | 2015-08-28 | 2016-11-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого" Министерства здравоохранения Российской Федерации | Способ диагностики генетической предрасположенности к развитию ишемического инсульта у больных с фибрилляцией предсердий |
| ES3009593T3 (en) * | 2016-02-08 | 2025-03-27 | Somalogic Operating Co Inc | Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof |
| WO2017156310A1 (en) * | 2016-03-09 | 2017-09-14 | Molecular Stethoscope, Inc. | Methods and systems for detecting tissue conditions |
| AU2017245701A1 (en) * | 2016-04-06 | 2018-08-23 | Société des Produits Nestlé S.A. | Biomarkers for predicting degree of weight loss |
| US20190159722A1 (en) * | 2016-04-15 | 2019-05-30 | Omron Corporation | Biological information analysis device, system, and program |
| CN105907857A (zh) * | 2016-04-29 | 2016-08-31 | 天津脉络生物科技有限公司 | 一种用于动脉血栓的分子标记物和试剂及其应用 |
| WO2017214684A1 (en) * | 2016-06-17 | 2017-12-21 | Adelaide Research & Innovation Pty Ltd | Methods and products for identifying conditions associated with cardiac fibrotic remodelling |
| ES2817087T3 (es) * | 2016-08-04 | 2021-04-06 | Hoffmann La Roche | ESM-1 (endocan) circulante en la evaluación de la fibrilación auricular |
| US11079394B2 (en) * | 2017-07-25 | 2021-08-03 | Vanderbilt University | Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure |
| WO2019115620A1 (en) * | 2017-12-13 | 2019-06-20 | Roche Diagnostics Gmbh | Circulating angiopoietin-2 (ang-2) and insulin-like growth factor-binding protein 7 (igfbp7) for the prediction of stroke |
| RU2685859C1 (ru) * | 2018-07-04 | 2019-04-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ прогнозирования риска развития ишемического инсульта |
| CN109192250B (zh) * | 2018-08-01 | 2021-12-07 | 华东理工大学 | 一种多相催化中克服表面物种快速迁移的加速模拟方法 |
| EP3833980A1 (en) * | 2018-08-10 | 2021-06-16 | F. Hoffmann-La Roche AG | Ces-2 (carboxylesterase-2) for the assessment of afib related stroke |
| WO2020037244A1 (en) * | 2018-08-17 | 2020-02-20 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Use of machine learning models for prediction of clinical outcomes |
| CN113302498B (zh) * | 2018-08-22 | 2024-07-30 | 豪夫迈·罗氏有限公司 | 循环spon-1（脊椎蛋白-1）在心房颤动评定中的应用 |
| JP2022512949A (ja) * | 2018-10-31 | 2022-02-07 | セントロ ナショナル デ インベスティガシオネス カルディオバスキュラレス カルロス テルセーロ （エフェ．エセ．ペ．） | 無症候性アテローム性動脈硬化症のバイオマーカー |
| KR102125053B1 (ko) * | 2018-12-14 | 2020-06-19 | 가톨릭대학교 산학협력단 | 심혈관계 질환의 검출용 조성물 및 이를 포함하는 키트 |
| EP3924972A4 (en) | 2019-02-14 | 2023-03-29 | Mirvie, Inc. | Methods and systems for determining a pregnancy-related state of a subject |
| GB201906052D0 (en) | 2019-04-30 | 2019-06-12 | Int Centre For Genetic Engineering And Biotechnology | Proteins with cardioprotective activity |
| US11030743B2 (en) * | 2019-05-16 | 2021-06-08 | Tencent America LLC | System and method for coronary calcium deposits detection and labeling |
| MX2022002314A (es) * | 2019-09-03 | 2022-06-02 | Somalogic Operating Co Inc | Prediccion del riesgo de eventos cardiovasculares y sus usos. |
| WO2021090909A1 (ja) * | 2019-11-06 | 2021-05-14 | 国立大学法人 香川大学 | 心不全マーカー |
| US10902955B1 (en) | 2020-05-01 | 2021-01-26 | Georgetown University | Detecting COVID-19 using surrogates |
| CA3179456A1 (en) * | 2020-05-19 | 2021-11-25 | Henricus J. DUCKERS | Detection and treatment of conditions characterized by perfusion shortage |
| FI130424B (en) * | 2020-06-18 | 2023-08-23 | Nightingale Health Oy | A method of determining whether a subject has a disease or condition or is at risk of developing a disease or condition |
| AU2021364805A1 (en) * | 2020-10-20 | 2023-05-18 | Somalogic Operating Co., Inc. | Cardiovascular event risk prediction |
| RU2750716C1 (ru) * | 2020-11-23 | 2021-07-01 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) | Способ прогнозирования сердечно-сосудистых осложнений у больных низкого или умеренного сердечно-сосудистого риска путем оценки их психологического статуса |
| WO2022165393A1 (en) * | 2021-02-01 | 2022-08-04 | Medtronic, Inc. | A method to identify lvad patients with elevated levels of blood activation using coupon tests |
| RU2757752C1 (ru) * | 2021-04-26 | 2021-10-21 | Общество с ограниченной ответственностью "Медицинская Технологическая Компания" (ООО МТК) | Способ определения индивидуального профиля факторов суммарного сердечно-сосудистого риска у пациента трудоспособного возраста |
| WO2023023748A1 (en) * | 2021-08-26 | 2023-03-02 | 3P Healthcare Pty Ltd | System and method for cardiovascular health assessment and risk management |
| EP4230233A1 (en) * | 2022-02-22 | 2023-08-23 | mimiX Biotherapeutics Sàrl | Method for producing tissue constructs |
| US20250259750A1 (en) * | 2022-04-15 | 2025-08-14 | Memorial Sloan-Kettering Cancer Center | Multi-modal machine learning to determine risk stratification |
| CN115932276B (zh) * | 2022-12-07 | 2025-09-02 | 首都医科大学附属北京安贞医院 | 一种检测生物标志物的产品在制备急性心肌梗死或其并发症的诊断的产品中用途 |
| WO2024226519A2 (en) * | 2023-04-24 | 2024-10-31 | Google Llc | Deep learning-based photoplethysmography model for cardiovascular risk prediction |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5660985A (en) * | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| EP1472352A4 (en) * | 2000-03-06 | 2005-10-12 | Smithkline Beecham Corp | NEW COMPOUNDS |
| US20030224501A1 (en) * | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| US6930085B2 (en) * | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
| HUE027779T2 (en) * | 2002-05-09 | 2016-11-28 | Brigham & Womens Hospital Inc | 1L1RL-1 is a marker of cardiovascular disease |
| AU2004256425A1 (en) * | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20050181451A1 (en) * | 2004-02-12 | 2005-08-18 | Bates Harold M. | Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants |
| US20090280108A1 (en) * | 2004-12-10 | 2009-11-12 | Da-Wei Gong | Serum amyloid a protein in inflammation and obesity |
| CN2783324Y (zh) * | 2005-04-28 | 2006-05-24 | 穆海东 | 心血管疾病诊断和预测多指标蛋白芯片检测试剂盒 |
| US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20070099239A1 (en) * | 2005-06-24 | 2007-05-03 | Raymond Tabibiazar | Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease |
| US20090226420A1 (en) * | 2005-11-10 | 2009-09-10 | Elizabeth Hauser | Methods of Determining the Risk of Developing Coronary Artery Disease |
| US20090004673A1 (en) * | 2006-01-31 | 2009-01-01 | Mitsubishi Kagaku Iatron, Inc. | Method for Determining Condition of Disseminated Intravascular Coagulation |
| EP2005168A4 (en) * | 2006-03-09 | 2009-05-20 | Biosite Inc | METHODS AND COMPOSITIONS FOR DIAGNOSING DISEASES OF AORTA |
| CA2659082A1 (en) * | 2006-06-07 | 2007-12-21 | Tethys Bioscience, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| EP1887361A1 (en) * | 2006-08-07 | 2008-02-13 | Bio-Rad Pasteur | Method for the prediction of vascular events |
| US7947447B2 (en) * | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| RU2376372C2 (ru) * | 2007-04-03 | 2009-12-20 | Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук | Способ генетической диагностики подверженности к сердечно-сосудистым заболеваниям |
| EP2019318A1 (en) * | 2007-07-27 | 2009-01-28 | Erasmus University Medical Center Rotterdam | Protein markers for cardiovascular events |
| US8461303B2 (en) * | 2007-08-02 | 2013-06-11 | Gilead Biologics, Inc. | LOX and LOXL2 inhibitors and uses thereof |
| GB0717637D0 (en) * | 2007-09-10 | 2007-10-17 | Univ Leiden | Future cardiac event biomarkers |
| WO2009075566A1 (en) * | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Biomarkers for cardiovascular disease |
| US20090186370A1 (en) * | 2008-01-18 | 2009-07-23 | Ogle Matthew F | Diagnostic biomarkers for vascular aneurysm |
| US8030097B2 (en) * | 2008-04-30 | 2011-10-04 | Versitech Limited and R & C Biogenius Limited | Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks |
| CN102186483A (zh) * | 2008-08-11 | 2011-09-14 | 德克萨斯大学系统董事会 | 促进血管完整性的微rna及其用途 |
| CN102203616A (zh) * | 2008-10-07 | 2011-09-28 | B.R.A.H.M.S有限公司 | 用于预测初次不利事件的生物标志物 |
| EP2440936A4 (en) * | 2009-06-08 | 2013-03-13 | Singulex Inc | GROUPS OF HIGHLY SENSITIVE BIOMARKERS |
| PT2264183T (pt) * | 2009-06-09 | 2017-03-14 | Gendiag Exe Sl | Marcadores de risco para doença cardiovascular |
| BRPI1010693A2 (pt) * | 2009-06-15 | 2019-07-16 | Cardiodx Inc | métodos implementados por computador para marcar e/ou pontuar uma primeira amostra obtida a partir de um sujeito, meios de armazenamento legível em computador de armazenamento de código de programa executável e métodos, sistema e kits de predição de cad em um sujeito |
| US9217747B2 (en) * | 2009-10-29 | 2015-12-22 | Health Diagnostic Laboratory, Inc. | Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes |
| CN102762743A (zh) * | 2009-12-09 | 2012-10-31 | 阿维埃尔公司 | 用于心血管疾病的诊断和分类的生物标记物检验 |
| CA2808233C (en) * | 2010-03-03 | 2017-07-11 | Somalogic, Inc. | Aptamers to 4-1bb and their use in treating diseases and disorders |
| KR102111624B1 (ko) * | 2011-09-30 | 2020-05-18 | 소마로직, 인크. | 심혈관 위험 사건 예측 및 그것의 용도 |
| CA2901394A1 (en) * | 2012-03-19 | 2013-09-26 | The Brigham And Women's Hosptial, Inc. | Growth differentiation factor (gdf) for treatment of diastolic heart failure |
-
2012
- 2012-09-28 KR KR1020147011813A patent/KR102111624B1/ko active Active
- 2012-09-28 CN CN201280058717.0A patent/CN103959060B/zh active Active
- 2012-09-28 EP EP12836076.5A patent/EP2761289B1/en active Active
- 2012-09-28 CN CN202210145010.9A patent/CN114518458A/zh active Pending
- 2012-09-28 US US13/631,567 patent/US20130085079A1/en not_active Abandoned
- 2012-09-28 RU RU2014110508A patent/RU2651708C2/ru active
- 2012-09-28 MX MX2014003153A patent/MX373248B/es active IP Right Grant
- 2012-09-28 BR BR122019023720-4A patent/BR122019023720B1/pt active IP Right Grant
- 2012-09-28 CA CA3074279A patent/CA3074279C/en active Active
- 2012-09-28 WO PCT/US2012/058060 patent/WO2013049674A1/en not_active Application Discontinuation
- 2012-09-28 SG SG11201400904SA patent/SG11201400904SA/en unknown
- 2012-09-28 ES ES12836076T patent/ES2777002T3/es active Active
- 2012-09-28 CN CN201710329039.1A patent/CN107102151A/zh active Pending
- 2012-09-28 JP JP2014533428A patent/JP6652781B2/ja active Active
- 2012-09-28 CA CA2847903A patent/CA2847903C/en active Active
- 2012-09-28 BR BR112014007214-0A patent/BR112014007214B1/pt active IP Right Grant
- 2012-09-28 IN IN1970CHN2014 patent/IN2014CN01970A/en unknown
- 2012-09-28 AU AU2013202112A patent/AU2013202112B9/en active Active
- 2012-09-28 KR KR1020207013434A patent/KR102248900B1/ko active Active
- 2012-09-28 SG SG10201906900QA patent/SG10201906900QA/en unknown
- 2012-09-28 CN CN201710064624.3A patent/CN107422126B/zh active Active
- 2012-09-28 SG SG10201607331WA patent/SG10201607331WA/en unknown
-
2013
- 2013-12-31 US US14/145,026 patent/US20150168423A1/en not_active Abandoned
-
2014
- 2014-03-06 IL IL231387A patent/IL231387A/en active IP Right Grant
- 2014-03-11 ZA ZA2014/01778A patent/ZA201401778B/en unknown
- 2014-03-14 MX MX2020004617A patent/MX2020004617A/es unknown
-
2018
- 2018-05-30 JP JP2018103211A patent/JP6546318B2/ja active Active
-
2019
- 2019-10-25 JP JP2019193933A patent/JP6917432B2/ja active Active
-
2020
- 2020-01-23 US US16/751,102 patent/US20200166523A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN01970A (enrdf_load_html_response) | ||
| MX2013001042A (es) | Biomarcadores de cancer pancreatico y usos de los mismos. | |
| IN2014CN01787A (enrdf_load_html_response) | ||
| EA030186B9 (ru) | Способ проведения количественных анализов | |
| MY170164A (en) | Aptamer-based multiplexed assays | |
| WO2014186761A3 (en) | Methods for determining responsiveness to an anti-cd47 agent | |
| WO2013052505A3 (en) | Methods and devices for assessing risk to a putative offspring of developing a condition | |
| WO2013075055A3 (en) | Kits and methods for assessing appendicitis | |
| EP3029153A3 (en) | Mesothelioma biomarkers and uses thereof | |
| HK1205764A1 (en) | Tuberculosis biomarkers and uses thereof | |
| WO2012177945A3 (en) | Diagnostic methods for eosinophilic esophagitis | |
| GB2515983A (en) | Methods and compositions for providing a preeclampsia assessment | |
| WO2013188686A3 (en) | Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome | |
| MX2016006125A (es) | Procedimiento, matriz y uso de los mismos. | |
| GB201014837D0 (en) | Biomarker signatures and uses thereof | |
| WO2011137388A3 (en) | Identification and use of biomarkers for detection and quantification of the level of radiation exposure in a biological sample | |
| MX2015001961A (es) | Metodos y sistemas para ensayos. | |
| IN2015DN01501A (enrdf_load_html_response) | ||
| WO2013112836A3 (en) | Diagnostic and prognostic biomarkers for cancer | |
| EP3557259A3 (en) | Methods and arrays for use in the same | |
| MX2015004419A (es) | Deteccion de analito y determinacion de concentracion de analito mediante uso de perlas magnetizables. | |
| GB201206323D0 (en) | Methods and arrays for use in the same | |
| WO2013043041A3 (en) | Methods and compositions for diagnosing familial hypercholesterolemia | |
| WO2014160237A3 (en) | Methods of prognosing preeclampsia | |
| WO2022266031A3 (en) | Renal insufficiency prediction and uses thereof |